Maze Therapeutics (Series D)
Funding Details
- Awarder
- Inbox
- Date Award
- June 08, 2025
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Funding Amount:
- $115,000,000
Company Info
- Company Description
- Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases.
- Market
- Renal, cardiovascular, and metabolic diseases
- Location
- South San Francisco, California, USA
- Coinvestors
- Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital, Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures